Topical Cyclosporine in Pediatric Keratoplasty

Purpose. To evaluate the efficacy and safety of combined treatment with 2% topical cyclosporine (CsA) and topical corticosteroid compared to treatment with topical corticosteroids only after pediatric keratoplasty. Methods. Twenty-two grafts in 16 pediatric patients were evaluated retrospectively. The eyes were divided into a CsA group (9 eyes) and a control group (13 eyes) based on the postoperative treatment regimen. Information reviewed included patient age and sex, clinical diagnosis; preoperative and postoperative intraocular pressure and lens status; previous, concurrent, and subsequent surgical procedures; operative and postoperative complications; number of graft rejections, timing of suture removal, and length of follow-up. The clinical outcome of penetrating keratoplasty (PK) was evaluated by the rate of rejection-free graft survival and graft survival evaluation by the Kaplan-Meier log-rank test. Results. The rejection-free graft survival rate was 88.9% in the CsA group and 38.5% in the control group. This difference in rejection-free graft survival rate between the groups was statistically significant (P = .0465). The graft survival rate was 88.9% in the CsA group and 46.2% in the control group. The difference in the graft survival rate was not statistically significant between the groups (P = .6). No clinical signs of systemic or local toxicity were seen with the topical CsA treatment. Conclusions. Two percent topical CsA is safe and effective in reducing the risk of allograft rejection in pediatric recipients.

[1]  J. Yada.  [Graft rejection]. , 2020, Kangogaku zasshi.

[2]  B. Reis,et al.  Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial☆ , 2000 .

[3]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. , 2000, Ophthalmology.

[4]  S. Whitcup,et al.  New developments in sustained release drug delivery for the treatment of intraocular disease , 1999, The British journal of ophthalmology.

[5]  M. Araie,et al.  [Long-term outcome of topical cyclosporine treatment following penetrating keratoplasty]. , 1999, Nippon Ganka Gakkai zasshi.

[6]  A. Kanellopoulos,et al.  Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. , 1998, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[7]  A. Kanellopoulos,et al.  Topical Cyclosporin A in the Management of Postkeratoplasty Glaucoma , 1997, Cornea.

[8]  H. Sencer,et al.  Topical cyclosporine as a possible new antimetabolite in trabeculectomy. , 1996, Ophthalmic surgery and lasers.

[9]  G. Foulks,et al.  Cytomegalovirus keratitis after penetrating keratoplasty. , 1995, Cornea.

[10]  J. Sugar,et al.  The indications for and outcome in pediatric keratoplasty. A multicenter study. , 1995, Ophthalmology.

[11]  Xiu-ying Jin,et al.  Local therapy of corneal allograft rejection with cyclosporine. , 1995, American journal of ophthalmology.

[12]  H. Geggel.  Successful penetrating keratoplasty in a patient with severe atopic keratoconjunctivitis and elevated serum IgE level treated with long-term topical cyclosporin A. , 1994, Cornea.

[13]  O. Ozden,et al.  Therapeutic use of topical cyclosporine. , 1993, Annals of ophthalmology.

[14]  M. Belin,et al.  Update on topical cyclosporin A. Background, immunology, and pharmacology. , 1990, Cornea.

[15]  R. Reznick,et al.  Survival analysis: A practical approach , 1989, Diseases of the colon and rectum.

[16]  M. Belin,et al.  Topical cyclosporine in high-risk corneal transplants. , 1989, Ophthalmology.

[17]  R. Nussenblatt,et al.  Cyclosporine: immunology, pharmacology and therapeutic uses. , 1986, Survey of ophthalmology.

[18]  F. Hoffmann,et al.  Lokale Behandlung des Hornhauttransplantates beim Menschen mit Cyclosporin A , 1985 .

[19]  R. D. Stulting,et al.  Penetrating keratoplasty in children. , 1984, Ophthalmology.

[20]  H. Demirci,et al.  Chemotherapy for retinoblastoma: a current topic. , 1999, Drugs.

[21]  J. Hill,et al.  Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. , 1994, Ophthalmology.

[22]  Y. Pouliquen,et al.  [Use of cyclosporin A eyedrops in the prevention of corneal graft rejection in man. I. Preoperative development of 4 eyes with metaherpetic keratitis]. , 1987, Journal francais d'ophtalmologie.

[23]  Y. Pouliquen,et al.  [Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results]. , 1987, Journal francais d'ophtalmologie.

[24]  M. Wiederholt,et al.  Topical cyclosporin A in the treatment of corneal graft reaction. , 1986, Cornea.